Elasmogen Ltd. has identified antibody-drug conjugates comprising antibodies covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer, autoimmune and inflammatory disorders.
Haisco Pharmaceutical Group Co. Ltd. has disclosed antibody-drug conjugates consisting of antibodies covalently linked to antitumor drugs through a linker reported to be useful for the treatment of cancer.
Crescent Biopharma Inc. has announced regulatory clearances of IND applications for CR-001 (SKB-118), a PD-1 x VEGF bispecific antibody, and CR-003 (SKB-105), an integrin β-6 (ITGB6)-targeted antibody drug-conjugate (ADC), both being developed for the treatment of advanced solid tumors.
Jiangsu Simcere Pharmaceutical Co. Ltd. has identified antibody-drug conjugates (ADCs) comprising antibody or antigen-binding fragments linked to a cytotoxic drug through a linker reported to be useful for the treatment of atopic dermatitis.
Innolake Biopharm (Hangzhou) Co. Ltd. has disclosed antibody-drug conjugates comprising bispecific antibodies covalently bound to exatecan through a linker reported to be useful for the treatment of cancer.
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was reported, with innovations spanning targets, linkers, payloads, conjugation chemistries and overall architectures. Once defined by a simple “one target, one payload” model, the field is lately expanding into a more versatile and diverse therapeutic space.
It’s been a year of two halves in Europe, with early optimism that the biotech sector had recovered from the post-pandemic funding drought being crushed by an investment slowdown from June onward.
Hainan Simcere Pharmaceutical Co. Ltd. has disclosed antibody-drug conjugates comprising a glycoengineered antibody covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
Shanghai Henlius Biotech Inc. has announced acceptance of IND applications by China’s National Medical Products Administration (NMPA) for three differentiated candidates for the treatment of solid tumors.
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was reported, with innovations spanning targets, linkers, payloads, conjugation chemistries and overall architectures. Once defined by a simple “one target, one payload” model, the field is lately expanding into a more versatile and diverse therapeutic space.
RSS
